Clinical trial NCT01047254: Bupropion for the Treatment of Apathy in Alzheimer's Dementia
Official title: A 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Bupropion for the Treatment of Apathy in Alzheimer's Dementia(Apa-AD)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Apathy in Dementia
Lead sponsor: University Hospital, Bonn
Sponsor class: OTHER
Collaborators: name: University of Cologne
name: Physician of neurology, psychiatry and psychotherapy Horn, MD; Bad Honnef
name: Charite University, Berlin, Germany
name: Universität Duisburg-Essen
name: University of Erlangen-Nürnberg
name: University of Freiburg
name: University Medical Center Goettingen
name: Universität des Saarlandes
name: Johannes Gutenberg University Mainz
name: Heidelberg University
name: Philipps University Marburg
name: Ludwig-Maximilians - University of Munich
name: University of Rostock
name: University Hospital Tuebingen
name: University of Ulm
First posted: 2010-01-12
Enrollment: 110
Sex: ALL
Minimum age (years): 55
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Apathy in dementia prevents successful application of non-pharmacological treatments, accelerates cognitive and functional decline and increases disease-related costs by earlier need for full-time care. Apathy is a distinct entity and occurs independently of other neuropsychiatric syndromes, like depression.

Today, there is no high-level evidence for any effective treatment of apathy in AD. In contrast to other neuropsychiatric syndromes in AD, like psychosis and depression, and despite its high prevalence and clinical relevance, apathy has never been the primary outcome in a clinical trial. Basic and clinical research has provided a distinct model of the pathophysiology of apathy with dopamine and norepinephrine as the key neurotransmitter systems involved. The antidepressant Bupropion is a dopamine and norepinephrine reuptake inhibitor. There is evidence from case-series, that Bupropion reduces apathy in patients with organic brain disorders. This study will test the efficacy and safety of Bupropion in the treatment of apathy in AD in a 12-week multicenter doubleblind placebo controlled trial. Secondary endpoints will be quality of life of patients, caregivers' distress, ability of patients to perform activities of daily living,utilization of healthcare resources by patients and by caregivers, and cognitive functions.


Eligibility criteria: Inclusion Criteria:

* Mild to moderate Alzheimer's dementia, male and female (NINCDS/ADRDA criteria)
* Presence of clinically relevant apathy defined by the Neuropsychiatric Inventory (NPI) apathy item (score of \>/= 4 points) and the Marin/Starkstein criteria for apathy
* MMSE: 10-25
* Outpatient status, not institutionalized
* Presence of reliable caregiver
* Stable treatment with antidementia drugs for at least three months prior to entry or no treatment with antidementia drugs

Exclusion Criteria:

* Other Dementia (e.g. vascular dementia, Lewy-body dementia, fronto-temporal dementia)
* Presence of a clinically relevant depression defined by either the NPI depression item (score \>/= 4 points) or DSM-IV criteria for major depressive episode (with depressed mood)
* Alcoholism and Benzodiazepine addiction
* Current treatment with antipsychotics and antidepressants (including St. John's wart)
* Current treatment with dopaminergic agents or Amantadin
* Current treatment with benzodiazepines
* Current treatment with MAO inhibitor (Bupropion contraindication)
* Known sensibility to Bupropion treatment
* Severe psychiatric disease (including hospitalization) in the last 6 months, suicide attempt, acute psychotic symptoms
* Severe physical illness, that do not allow a participation in a 12-week period of treatment
* Medical history with seizures
* Medical history with tumors of the central nervous system
* Severe craniocerebral injury and medical history with cerebral substance defect
* Clinically relevant renal disease, liver insufficiency
* Simultaneous treatment, which reduces the seizure threshold (e.g. antipsychotics, antidepressants, antimalarial agents, Tramadol, Theophyllin, systemic steroids in higher dose, Chinolone, sedative antihistamines)
* Simultaneous treatment, which is metabolized through Cytochrom P450-Isoenzym 2D6 (e.g. these beta blockers: Metoprolol, Proanolol, Timolol, Carvediol, Nebivolol, Typ-1C-Antiarrhyhtmics for e.g. Propafenon, Flecinid) (except Donepezil and Galantamin)
* Simultaneous treatment with drugs, which may interfere with the metabolization of Bupropion (e.g. Carbamazepin, Phenytoin, Valproat, Ritonavir, Lopinavir)
* Diabetes mellitus, which is therapeutically poorly regulated and treated by medication
* Treatment with stimulants and appetite depressants
* Participation in other clinical trials with in the last 3 months
* Suicidal tendency
* Known lactose intolerance

Primary outcomes:
measure: Change in Apathy Evaluation Scale (AES) score
timeFrame: 12 weeks
Secondary outcomes:
measure: NPI total score;NPI caregivers' distress total score;ADCS-ADL; QoL-AD; RUD;ADAScog;MMSE
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Bonn
country: Germany
facility: Department of Psychiatry, University Bonn
Study officials:
affiliation: University Bonn
name: Frank Jessen, MD
role: PRINCIPAL_INVESTIGATOR
References: